Predict your next investment

HEALTHCARE | Biotechnology
sextonbiotechnologies.com

See what CB Insights has to offer

Founded Year

2019

Stage

Acquired | Acquired

Total Raised

$5.25M

Valuation

$0000 

About Sexton Biotechnologies

Sexton Biotechnologies advances a portfolio of container closure and media supplementation tools for cell and gene therapy bioproduction.On August 9th, 2021, Sexton Biotechnologies was acquired by BioLife Solutions at a valuation of $30M.

Sexton Biotechnologies Headquarter Location

1102 Indiana Ave.

Indianapolis, Indiana, 46202,

United States

812-339-2235

Latest Sexton Biotechnologies News

BioLife Solutions Acquires Biotech Startup Sexton Biotechnologies

Sep 4, 2021

By Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team Indianapolis-based Biotech startup Sexton Biotechnologies has been acquired by Biolife Solutions, a leading company providing biological products for cell and gene therapies in the vast biological market. Founded in 2019 with funding from Cook Regentec, BioCrossroad, Casdin Capital, and BioLife Solutions, Sexton was spun off from Cook Regentec. The startup specializes in the development and […] / share Published on September 4, 2021 Indianapolis-based Biotech startup Sexton Biotechnologies has been acquired by Biolife Solutions , a leading company providing biological products for cell and gene therapies in the vast biological market. Founded in 2019 with funding from Cook Regentec, BioCrossroad, Casdin Capital, and BioLife Solutions, Sexton was spun off from Cook Regentec. The startup specializes in the development and supply of biomanufactured products for gene and cell therapy. As a landmark for Cook Regentec, Sexton develops bioengineering tools and vehicles with flexible automation and cell-manufacturing capabilities that increase the probability of a positive clinical outcome, reduce costs and save time. The startup has started gene and cell therapy clinical trials with several of its products, including proprietary sealed vials for cell therapy encapsulation, human platelet lysate media, and serum used in cell manufacturing and automated cell processing machines. In 2019 Sexton’s portfolio includes the Signata CT-5 liquid handling system, the CellSeal platform of cold storage tools and filling/finishing systems, and human platelet lysate growth supplements. President and CEO of BioLife Solutions, Mike Rice commented on his investments and welcomed Sexton to be a partner of the company: “Our team has identified and closed six acquisitions in the last two and a half years, assembling a portfolio of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. We welcome Team Sexton to BioLife and look forward to the contributions of Sexton’s consumable products to our growing revenue base.” Some of BioLife Solutions’ typical investment products can be listed as proprietary CryoStor® cryogenic media, HypoThermosol® transport and storage media, ThawSTAR® waterless automatic defrost product line, Custom Biogenic Systems® high capacity freezers, evo® cold chain management systems, Stirling Ultracold ULT freezers, and SciSafe biomaterials storage. With the biotech industry gaining ground as funding opportunities increase in the post-COVID19 economy, startups like Sexton are becoming increasingly attractive for established companies to boost their operations. Tags

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sexton Biotechnologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sexton Biotechnologies is included in 4 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.